Recent studies have demonstrated that anti-LAG-3 monotherapy and/or combinations of anti-LAG-3 and anti-PD-1 represent a good treatment for LAG-3+ ccRCC patients who develop an important resistance to anti-PD-1 drugs. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.